into a Material Definitive Agreement.
December 3, 2019 (the “Second Closing”), Protagenic Therapeutics, Inc. (the “Company”) entered into seven
Convertible Note Purchase Agreements (each, a “Purchase Agreement”) with seven accredited investors (collectively
the “Investors”), pursuant to which the Company issued and sold unsecured convertible promissory notes (the “Notes”)
to the Investors in the aggregate principal amount of $205,000. The Company may issue additional Notes in the future, up to an
aggregate of $2,500,000 principal amount of Notes (the “Private Offering”). The Company had previously issued Notes
in the aggregate principal amount of $350,000, as reported in a Current Report on Form 8-K filed on November 21, 2019.
Notes are due on November 6, 2023 (the “Maturity Date”) and accrue simple interest at an annual rate of 6% on the
aggregate unconverted and outstanding principal amount, payable annually, beginning October 31, 2020. The Company will pay (a
“PIK Payment”) the interest due by adding such interest (including interest at the Default Rate, as defined below,
if any) to the then-outstanding principal amount of the Notes on each interest payment date and on the Maturity Date. Each PIK
Payment will be preceded by written notice from the Company to the Note holder setting forth in reasonable detail the amount of
such PIK Payment and the principal amount of the Note following such PIK Payment. The Notes will bear interest at the rate of
12% per year (the “Default Rate”) following a default.
may convert their Notes (including accrued interest) at their option, in whole or in part, at any time prior to the Maturity Date,
at a conversion price (the “Conversion Price”) of $1.25 per share of the Company’s common stock, par value $0.0001
per share (the “Common Stock”). The Conversion Price is subject to adjustment for any stock dividend, stock split,
combination or other similar recapitalization event. On the Maturity Date, the Company will repay the Notes (including accrued
interest) in their entirety in cash or, at its option, in shares of Common Stock at the Conversion Price.
Company may redeem for cash or Common Stock all or any portion of the Notes, at its option, on or after November 5, 2021 if the
last reported sale price of its Common Stock has been at least 120% of the Conversion Price then in effect for at least 20 trading
days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately
preceding the date on which it provides notice of redemption. The redemption will be effected at a redemption price equal to 100%
of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
Any such redemption must be applied ratably among all Convertible Notes in proportion to their respective outstanding principal
balances, plus accrued and unpaid interest. Other than pursuant to this redemption right, the Company may not pre-pay the Notes.
following events, among others, constitute an event of default under the Notes: (i) failure to pay when due any obligations under
the Notes, (ii) any representation or warranty of the Company under the Purchase Agreements and the other documents contemplated
by the Purchase Agreement, including the Notes (collectively, the “Loan Documents”) being untrue in any material respect
as of the date made, (iii) any breach by the Company of any covenant in the Loan Documents, after a cure period, (iv) a material
judgment or judgments are rendered against the Company, (v) the Company makes an assignment for the benefit of creditors or (vi)
an involuntary proceeding in bankruptcy (or similar proceeding) is filed against the Company. Defaults may only be declared by
the holders of a majority of the principal amount of the Notes then outstanding (a “Holder Majority”).
stockholder approval of the issuance of the Notes is required under applicable NASDAQ or other stock exchange listing rules in
order for the Company to issue shares of Common Stock upon conversion of the Notes, the Company is obligated to call one or more
meetings of the stockholders for purposes of such approval.
Notes and the shares of Common Stock underlying the Notes have not been registered under the Securities Act of 1933, as amended,
and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
paid the Placement Agent (the name of which will be disclosed on a subsequent Current Report on Form 8-K), including its sub-agents,
a commission of 8% of the funds raised at the Second Closing from investors introduced by the Placement Agent. In addition, the
Placement Agent received warrants (the “Placement Agent Warrants”) to purchase a number of shares of Common Stock
equal to 10% of the shares of Common Stock issuable upon conversion of the Notes sold to the investors at the Second Closing who
were introduced by the Placement Agent. As a result of the foregoing arrangement, at the Second Closing, the Placement Agent (including
its sub-agents) was paid commissions of $16,400 and was issued Placement Agent Warrants to purchase 16,400 shares of Common Stock
at an exercise price of $1.25 per share.
summary set forth above does not purport to be complete and is qualified in its entirety by reference to the forms of Purchase
Agreement and Note filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K, which are incorporated by reference herein.
Company’s wholly-owned subsidiary, Protagenic Therapeutics Canada (2006) Inc., a corporation formed under the laws of the
Province of Ontario, Canada, has guaranteed (the “Guaranty”) the full and prompt payment of all obligations when due
under the Notes. All actions by the Note holders under the Guaranty may only be taken upon the written consent of a Holder Majority.
summary set forth above does not purport to be complete and is qualified in its entirety by reference to the Guaranty filed as
Exhibit 10.3 to this Current Report on Form 8-K, which is incorporated by reference herein.